NASDAQ:ALTH - Allos Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Allos Therapeutics (NASDAQ:ALTH)

Allos Therapeutics logoAllos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. FOLOTYN can be delivered as a single agent, for which the Company has approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and can be used in combination therapy regimens. On September 5, 2012, Spectrum Pharmaceuticals, Inc. acquired Allos Therapeutics, Inc.

Receive ALTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ALTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Allos Therapeutics (NASDAQ:ALTH) Frequently Asked Questions

What is Allos Therapeutics' stock symbol?

Allos Therapeutics trades on the NASDAQ under the ticker symbol "ALTH."

Has Allos Therapeutics been receiving favorable news coverage?

News headlines about ALTH stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Allos Therapeutics earned a daily sentiment score of 0.24 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Allos Therapeutics?

Shares of ALTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Allos Therapeutics?

Allos Therapeutics' mailing address is 11080 Circle Point Rd Ste 200, WESTMINSTER, CO 80020-2778, United States. The biopharmaceutical company can be reached via phone at +1-303-4266262.

MarketBeat Community Rating for Allos Therapeutics (ALTH)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  102
MarketBeat's community ratings are surveys of what our community members think about Allos Therapeutics and other stocks. Vote "Outperform" if you believe ALTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALTH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allos Therapeutics (NASDAQ:ALTH) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/27/2016 forward)


Allos Therapeutics (NASDAQ:ALTH) Earnings History and Estimates Chart

Earnings by Quarter for Allos Therapeutics (NASDAQ:ALTH)

Allos Therapeutics (NASDAQ ALTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2012Q1 2012($0.05)($0.11)ViewN/AView Earnings Details
3/6/2012($0.09)($0.01)ViewN/AView Earnings Details
11/3/2011($0.16)($0.11)ViewN/AView Earnings Details
8/4/2011($0.14)$0.02ViewN/AView Earnings Details
5/10/2011($0.15)($0.14)ViewN/AView Earnings Details
3/3/2011($0.18)($0.17)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.20)($0.18)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.20)($0.19)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.22)($0.20)ViewN/AView Earnings Details
3/1/2010Q4 2009($0.20)($0.22)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.21)($0.21)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.18)($0.19)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.17)($0.19)ViewN/AView Earnings Details
3/3/2009Q4 2008($0.16)($0.18)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.16)($0.16)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.17)($0.16)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.17)($0.18)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.16)($0.17)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Allos Therapeutics (NASDAQ:ALTH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Allos Therapeutics (NASDAQ ALTH) Insider Trading and Institutional Ownership History

Insider Trading History for Allos Therapeutics (NASDAQ:ALTH)

Allos Therapeutics (NASDAQ ALTH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


Allos Therapeutics (NASDAQ ALTH) News Headlines

No headlines for this company have been tracked by

SEC Filings

Allos Therapeutics (NASDAQ:ALTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Allos Therapeutics (NASDAQ:ALTH) Income Statement, Balance Sheet and Cash Flow Statement


Allos Therapeutics (NASDAQ ALTH) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.